

Study Inhibitory Effects Of Lactobacillus Plantarum Against Staphylococcus Aureus Methicillin Resistance

Mohammed Subhi Musa

Biology department, College of science, University of Kirkuk

Corresponding author: Mohammadsbhi@uokirkuk.edu.iq

DOI: 10.47750/pnr.2022.13.S08.212

Abstract

The current study aimed to study effects of *Lactobacillus plantarum* on *Staphylococcus aureus* that isolated from different clinical sources (burns, wounds, urine). The results showed the distribution rates of isolates for the sources from which bacteria were isolated. The highest percentage of burns sources was 85.7%, followed by wounds sources 83.3% and urine 60%. These isolates of *S. aureus* showed 100% resistance against Vancomycin, 90% against Tetracycline and Methicillin, 85% and 83% to Penicillin and Erythromycin, respectively, and 80% for both Ciprofloxacin and Oxacillin, the resistance was 75% and 74% to Novobiocin and Levofloxacin, respectively, while the rest of the antibiotics Trimethoprim / Sulfa Methoxamine recorded 51%, and Rifampicin and Ofloxacin had a resistance ratio of 38% and 5%, respectively. It was observed in this study the *Lactobacillus plantarum* broth culture appeared inhibitory activity against isolates of *Staphylococcus*. While the supernatant did not give inhibitory activity except for the isolate of Staph3. Also, it was observed that the biofilm of all methicillin-resistant *S. aureus* isolates using *Lactobacillus plantarum* broth showed significant differences compared to control. In addition, the scanning electron microscope results showed a decrease in the thickness of the biofilm after treatment with *L. plantarum*.

Keywords: *Lactobacillus plantarum*, *Staphylococcus aureus*, Methicillin resistance

Introduction

Staphylococcus aureus is a diffuse, and highly adaptable pathogen that colonizes the skin and mucous membranes of the anterior nose, gastrointestinal tract, peritoneum, urogenital tract, and pharynx (den Heijer et al., 2013), and is the causative agent of a variety of human and animal diseases. Which has a significant impact on public health (Luzzago et al., 2014; Bitrus et al., 2018). It demonstrates the opportunistic pathogenic behaviour of *Staphylococcus aureus* in both humans and animals, and can cause several disorders such as suppurative dermatitis or abscesses, endocarditis, sepsis, and urinary tract infections, mastitis, meningitis, osteomyelitis, food poisoning, biofilm-related infections and septicaemia (Singh, 2017; Scudiero et al., 2020). It represents of the most common bacterial causes of skin infection. *Staphylococcus aureus* is responsible for folliculitis, furunculosis, impetigo, syndrome of toxic shock, etc (Saha et al., 2019).

Staphylococcus aureus resistance to penicillin appeared due to its production of the enzyme β -lactamase, where methicillin was synthesized to resist the degradation of beta-lactamase, but MRSA strains were identified that were resistant to all β -lactam antibiotics, and soon after the introduction of methicillin into clinical practice, until recently MRSA was predominantly a pathogen that causes hospital-acquired infections, but MRSA strains are now increasingly isolated from community-acquired infections as well. Recent years have caused great public health concerns and made MRSA infection more difficult for clinicians to treat (Palavecino, 2007). *Staphylococcus*

aureus is the most common, virulent and pathogenic type of bacteria that is easily transmitted through hospitals, and is usually resistant to a variety of antibiotics, which makes the infection difficult to treat (Cooper et al., 2014). For this reason, researchers attempt to find other types of antibiotics, including penicillin compounds, such as Methicillin, Nafcillin, and strains of methicillin-resistant cocci spread and constitute a major problem in many hospitals and health care centres (Fagade et al., 2010).

Recent studies point to probiotics as a promising option for fighting biofilms. Probiotics are live microorganisms which, when administered in sufficient quantities, are of health benefit to the host.” Lactic acid bacteria which include: Lactobacillus, Bifidobacterium, Streptococcus, Lactococcus and Leuconostoc are the dominant group of bacteria with proven probiotic effect, where Lactobacillus is more effective. This group of bacteria can grow in different habitats using diverse sources of carbon. From glucose metabolism, lactic acid bacteria are classified as fermenters, producing exclusively lactic acid, and producing many other metabolites besides lactic acid, such as ethanol and acetic acid (Carvalho et al.,2021).

Methods

Sample collection

Two hundred fifty Samples were collected from different sources (burns, wounds, and urine) of *S. aureus* isolates from patients admitted to Hawija Hospital / Kirkuk city.

Isolation and identification of *S. aureus*

The isolates of *S. aureus* were diagnosed microscopically and biochemically tests (Coagulase, Oxidase, Catalase, Urea test, DNase).Also , it was used API 20 to diagnosis this bacteria. Moreover , *S. aureus* methicillin resistance detected by using CHROMagar MRSA

Antibiotics sensitivity test of *S. aureus*

S. aureus isolates were cultivated bacteria on Blood Agar. The disc diffusion method for the microbial sensitivity test depended on the Kirby Bauer method and Mueller Hinton agar was performed for all *S. aureus* isolates to determine their antibiotic resistance (Melo et al., 2013).

Detection of biofilm formation

It was detected biofilm by using Congo red agar and the plate consisting of micro-calibration tubes (Mathur et al.,2006)

Antagonistic effect of Lactobacillus on *S. aureus*

Lactobacillus plantarum(L.p) was obtain from Selçuk University/Turkey .It was used to inhibition of *S. aureus* methicillin resistance. Where it was applied suspension and supernatant of Lactobacillus plantarum to detect using agar diffusion to detect activity against four isolates of *S. aureus*.

Results and discussion

Distribution of Staphylococcus aureus isolates from different sources

The results showed the distribution rates of isolates for the sources from which bacteria were isolated. The highest percentage of burns sources was 85.7%, followed by wounds sources 83.3% and urine 60% as shown in Table 1.

Source	Number samples	Percentage %
Wounds	30	83.3 (30/25)
Burn	70	85.7(60 /70)
Urine	50	60(30/50)

Table 1.The prevalence percentage of *Staphylococcus aureus* isolates from different sources

One study showed that out of 666 bacteria isolated from clinical samples, 133 samples (19.96%) belong to *Staphylococcus aureus*, 79 samples (78.95%) of them are isolated from pus and wound infections. Among the 133 samples of *Staphylococcus aureus*, 94 (70.64%) of *Staphylococcus aureus* were resistant to methicillin, as the prevalence of *Staphylococcus aureus* was highest in wounds and pus. *S. aureus* is one of the known pathogens, still one of the most common causes of infection pyogenic tissue in humans (Sapkota et al., 2019). While in other studies its prevalence was 30.4% and 14.4%, and other studies conducted globally also showed similar results (Shahi et al., 2018 ; Bhatt et al., 2014). *S. aureus* is a natural bacterium from the normal skin flora that can enter the body through broken skin, cuts, surgical wounds, burns and intravenous catheters where it causes purulent infections. And the percentage of its prevalence in burns and wounds, which indicates its main role in purulent soft tissues and wound infections. It was also observed that the rate of isolation of *S. aureus* bacteria in the pus samples was higher compared to the other samples (Shahi et al., 2018; Khanal et al., 2018). Some studies also showed that the prevalence of *Staphylococcus aureus* was 28.6% of hospital environments (Cheatham et al., 2019). Another study showed that *S. aureus* was isolated, its prevalence was 21.46% (50 samples from 233 samples) for different environments. The prevalence of hand swabs was 19.23% (Tibebu et al., 2021).

Detection of *Staphylococcus aureus*

The number of isolates obtained was *S. aureus* 130 samples out of 250 samples .The microscopic examination of the isolates showed that they are Gram-positive in pairs, and often in clusters, as they appeared in the form of short chains, and they do not contain a capsule and do not contain spores (Versalovic, 2011).The results of biochemical tests showed that all isolates of *Staphylococcus aureus* were positive for the tests (coagulase, oxidase, catalase, urea test and DNase)as shown figure 1 (McFaddin, 2000; Brooks et al., 2014).The diagnosis of *Staphylococcus aureus* was confirmed using API 20 and Vitek 2Compact.




Figure1. Biochemical test of *Staphylococcus aureus* (A)Coagulase (B)Urea test (C) Oxidase



Figure2. Biochemical test of Staphylococcus aureus DNase test

Also, it was tested 30 isolates for their resistance to methicillin using Methicillin and all of them were resistant to Methicillin (100%) as shown in Figure 3 and 4.



Figure3. Staphylococcus aureus CHROM agar MRSA

It agreed with several studies to detect the resistance of bacteria to methicillin, one of study showed the resistance of Staphylococcus aureus isolates to Oxacillin 100% (Jahan et al., 2015). So the percentage of resistant isolates was 37.5% out of 165 samples tested (Pillai et al., 2012), and CHROM agar MRSA was also used to ensure the accuracy of diagnosing. Studies of CHROM agar MRSA for its ability to identify Methicillin-Resistant Staphylococcus aureus (MRSA), as 216 isolates of MRSA were methicillin-resistant and 241 of 226 MRSA-susceptible isolates (Diederer et al., 2005). Another used the CHROM agar MRSA, 29 isolates (25%) of the isolates diagnosed with methicillin resistance using CHROM agar MRSA medium, the sensitivity, specificity, and accuracy of CHROM agar MRSA 100%, 98.86%, and 99.13%, respectively. Thus CHROM agar MRSA could be a good, rapid and accurate selection for methicillin-resistant *S. aureus* (Chowdhury et al., 2014).

Antibiotic sensitivity

The results of the antibiotic sensitivity test (Figure 4) were shown against methicillin-resistant Staphylococcus aureus isolates. These isolates showed 100% resistance against Vancomycin, 90% against Tetracycline and Methicillin, 85% and 83% to Penicillin and Erythromycin, respectively, and 80% for both Ciprofloxacin and Oxacillin, the resistance was 75% and 74% to Novobiocin and Levofloxacin, respectively, while the rest of the antibiotics Trimethoprim / Sulfa Methoxamine recorded 51%, and Rifampicin and Ofloxacin had a resistance ratio of 38% and 5%, respectively.




Figure 4.The percentage of antibiotics resistance against *Staphylococcus aureus* (MRSA)

The current study showed similar results of some studies in the resistance of methicillin-resistant *Staphylococcus aureus* (MRSA) isolates to some antibiotics (Gurung et al., 2020). In other studies, most *S. aureus* isolates were shown to be highly resistant to penicillin (71.92%), oxacillin (58.97%), and moderately resistant to tetracycline (38.49%). While it is resistant to ciprofloxacin (5.12%), chloramphenicol (2.56%), trimethoprim/sulfamethoxazole (2.56%), vancomycin (0%), and gentamicin (0%) (Bokharai et al., 2020). In addition to another study, it was observed that *S. aureus* bacteria isolated from UTI patients were sensitive to Linezolid, chloramphenicol, and quinupristin/dalfopristi and resistant to nitrofurantoin, tetracycline, erythromycin and ciprofloxacin (Yousefi et al., 2016). Also, in one study, methicillin-resistant *S. aureus* had a 45% resistance against Trimethoprim/Sulfa Methoxamine (Sato et al., 2022). While in another study, methicillin-resistant *S. aureus* had the highest prevalence of resistance against penicillin (100%), ceftaroline (100%), tetracycline (100%), gentamicin (83.33%) trimethoprim-sulfamethoxazole (80.55%) (Abdolmaleki et al., 2019). The resistance of bacteria to Rifampicin is also through the inhibition of RNA synthesis in bacteria. Thus, resistance is produced through a change in RNA polymerase as a result of a chromosomal mutation (Brooks et al., 2014). The pathogen that causes infection may vary according to its geographical spread, and therefore resistance strains must be identified and appropriate treatment found depending on the prevalence of resistance in the region (Looney et al., 2017).

Detection of biofilm formation

The biofilm of *Staphylococcus aureus* was detected using Congo red agar medium, where 30 methicillin-resistant isolates were tested and 80% gave positive results. A change in the color of the medium appeared from red to black as a result of biofilm production as shown in Figure (5).




Figure 5.Biofilm formation *Staphylococcus aureus*

The plate consisting of micro-calibration tubes was used to detect the formation of biofilms of methicillin-resistant *Staphylococcus aureus* by reading the optical density using ELISA. The strong biofilm production gave a reading of optical density higher than 0.5 nm, Where 30 isolates were tested from different sources and 10 isolates were each of the sources of urine, wounds and burns. The percentages of isolates with strong production of biofilm were 70% (21 isolates), and isolates of weak production were 20% (6 isolates), and isolates of medium production were 10% (3 isolates).




Figure 6 .The percentage of biofilm formation for different sources of *Staphylococcus aureus*

One study showed the ability of *Staphylococcus aureus* isolates to produce biofilm strongly (53%) isolated from different medical sources represented by wounds, burns, urine, pus and saliva (Abd Halim et al., 2018). Another study also recorded a high percentage of *Staphylococcus aureus* *S. aureus* bacteria produce biofilms by 64.89% (Fatima et al., 2011) and 36% (Akinkunmi and Lamikanra 2012), and another study indicated the ability of *S. aureus* bacteria to produce biofilms by 38%, this may be due to the difference in the sources that Bacteria strains were isolated from them (Ramakrishna et al., 2014).

Another study showed that 52.6% of the isolates of *Staphylococcus aureus* isolated from humans were biofilm producers. Where it was found that the clinical isolates in humans that form the biofilm are more than the coexisting isolates in animals (Acheke et al., 2020). Biofilm formation is an important cause of all types of *Staphylococcus* associated with nosocomial infections. Biofilms produced by staphylococci isolated from other clinical samples are of clinical interest because biofilms constitute a pathogen reservoir and are associated with resistance to antimicrobial agents and chronic infections (Ramakrishna et al., 2014).

Biofilm production is one of the most important virulence factors in *S. aureus* because it enables it to resist or inhibit the effect of various antibiotics. The genes responsible for biofilm production were found in 50% of *S. aureus* biofilm producing bacteria (El-Nagdy et al., 2020). These biofilms often serve as a source of recurrent infections. Biofilm-associated infection is a significant problem, because biofilm-associated bacteria can withstand host immune defences, and antibiotics (Hancock et al., 2010). Higher rates of multidrug resistance and methicillin resistance were found among the biofilm-producing strains compared to the non-biofilm-producing strains (Belbase et al., 2017).

Antagonistic activity test of *Lactobacillus* on methicillin-resistant *Staphylococcus aureus* (MARSA)

Lactobacillus plantarum (L.p) was tested to detect antibacterial activity against methicillin-resistant *Staphylococcus aureus*, and *Lactobacillus* supernatant and broth culture were used by agar diffusion method.

The results showed through the diameters of inhibition (Table 2 and 3) that *Lactobacillus plantarum* gave inhibitory activity against isolates of *Staphylococcus*. While the supernatant did not give inhibitory activity except for the isolate of Staph3.

Table 2. Inhibition diameters of bacterial culture of *Lactobacillus plantarum* towards methicillin-resistant *Staphylococcus aureus* isolates.

MARSA	L.p2	L.p1
Staph1	8	8
Staph2	14	9
Staph3	7	8
Staph4	9	10

Table 3. Inhibition diameters of bacterial supernatant of *Lactobacillus plantarum* towards methicillin-resistant *Staphylococcus aureus* isolates.

MARSA	L.p2	L.p1
Staph1	0	0
Staph2	0	0
Staph3	2	3
Staph4	0	0

During several studies, including Kubba (2006) noted that the inhibitory effect of *Lactobacillus* spp. It was higher in MRS liquid medium as it has a stimulating effect on *Lactobacillus* bacteria which inhibits Gram-negative and Gram-positive bacteria. It was also noted that the three isolates of *Lactobacillus* bacteria, *L. acidophilus*, *L. plantarum* *L. casei*, Where they had an inhibitory effect on bacteria with inhibition diameters of 13.6 mm, 10.3 and 10.6, as well as a mixture of these types was used and they had a strong inhibitory effect when mixed with them with inhibition diameters The highest ranges between 14.3-20.3 mm (Bhola and Bhadekar, 2019).

Also Xu et al.(2020) showed that *L. casei* inhibits the growth of *Bacillus cereus*, *Staphylococcus aureus*, *Salmonella typhimurium* and *Escherichia coli*. In another study, the activity of *L. acidophilus*, *L.casei* bacteria against methicillin-resistant *S. aureus* was observed when grown on solid and liquid media of a mixture of *Lactobacillus* bacteria of the species used with methicillin-resistant *S. aureus*, where as a result of the antagonistic reaction between them, the methicillin-resistant bacteria were eliminated with 99% after an incubation period of 24 hours at 37°C (Karska-Wysocki et al., 2010).

Antagonistic activity test of *Lactobacillus* on biofilm formation for methicillin-resistant *Staphylococcus aureus* (MARSA)

The results showed (Table 4 and 5) the antibacterial effect of *Lactobacillus* towards the biofilm of methicillin-resistant *S. aureus* isolates, as it was observed that the biofilm of all methicillin-resistant *S. aureus* isolates using *Lactobacillus plantarum* broth showed significant differences compared to isolates that were not treated with *Lactobacillus* bacteria. The results of using *Lactobacillus* supernatant also showed a decrease in the biofilm formation of *S. aureus* when treated with the supernatant.

Table 4. Inhibitory effect of *Lactobacillus plantarum* on the biofilm formation by *S. aureus*

Isolates of <i>S. aureus</i>	<i>L. plantarum</i>	O.D630nm Control	O.D 630nm Treatment
Staph1	L.p1	0.94±0.05a	0.310±0.2b
	L.p2	0.87±0.12a	0.315±0.1b

Staph2	L.p1	0.78±0.6a	0.520±0.3b
	L.p2	0.95±0.62a	0.330±0.5b
Staph3	L.p1	0.88±0.05a	0.590±0.2b
	L.p2	0.9±0.2a	0.300±0.4b
Staph4	L.p1	0.74±0.4a	0.266±0.09b
	L.p2	0.68±0.35a	0.240±0.7b

Different letter in rows indicated significant differences (P<0.05)

Table 5. Inhibitory effect of *Lactobacillus plantarum* on the biofilm formation by *S. aureus*

Isolates of <i>S. aureus</i>	<i>L. plantarum</i>	O.D630nm Control	O.D 630nm Treatment
Staph1	L.p1	0.66±0.06a	0.270±0.02b
	L.p2	0.7±0.4a	0.560±0.2a
Staph2	L.p1	0.3±0.6a	0.237±0.1a
	L.p2	0.54±0.7a	0.32±0.06a
Staph3	L.p1	0.52±0.09a	0.485±0.6a
	L.p2	0.53±0.08a	0.493±0.5a
Staph4	L.p1	0.51±0.15a	0.45±0.09a
	L.p2	0.64±0.5a	0.55±0.4a

Different letter in rows indicated significant differences (P<0.05)

Several studies on the susceptibility of *Lactobacillus* bacteria to inhibit biofilm and antagonistic of *S. aureus* showed that the surfactants produced by *Lactobacillus acidophilus* had an inhibitory effect on microbes (*S. aureus*, *E.coli*, *Pseudomonas aeruginosa* and *Micrococcus luteus*). Also, the antibacterial effect of surfactants against *S. aureus* depends on their concentrations (Nataraj et al.,2021). *Lactobacillus* bacteria contain surfactants that are produced by a variety of microorganisms with different biological functions. Whereas lactic acid bacteria were examined for their emulsifying properties. The ability of *Lactobacillus plantarum* to produce surface-active peptides was verified. Biosurfactant derived from *L. plantarum* has been shown to have the ability to reduce surface tension (Al-Seraih et al., 2022).

Conclusions

It was observed in this study the *Lactobacillus plantarum* broth culture appeared inhibitory activity against isolates of *Staphylococcus*. While the supernatant did not give inhibitory activity except for the isolate of *Staph3*. Also, it was observed that the biofilm of all methicillin-resistant *S. aureus* isolates using *Lactobacillus plantarum* broth showed significant differences compared to control. In addition, the scanning electron microscope results showed a decrease in the thickness of the biofilm after treatment with *L. plantarum*

References

1. Abdel Halim, R. M., Kassem, N. N., & Mahmoud, B. S. (2018). Detection of Biofilm Producing Staphylococci among Different Clinical Isolates and Its Relation to Methicillin Susceptibility. Open access Macedonian journal of medical sciences, 6(8), 1335–1341.
2. Abdolmaleki, Z., Mashak, Z., & Safarpour Dehkordi, F. (2019). Phenotypic and genotypic characterization of antibiotic resistance in the methicillin-resistant *Staphylococcus aureus* strains isolated from hospital cockroaches. Antimicrobial Resistance & Infection Control, 8(1), 1-14.
3. Achek, R., El-Adawy, H., Hotzel, H., Hendam, A., Tomaso, H., Ehrlich, R., Neubauer, H., Nabi, I., Hamdi, T. M., & Monecke, S. (2021). Molecular Characterization of *Staphylococcus aureus* Isolated from Human and Food Samples in Northern Algeria. Pathogens (Basel, Switzerland), 10(10), 1276.
4. Akinkunmi, E. O., & Lamikanra, A. (2012). Phenotypic determination of some virulence factors in staphylococci isolated from faecal samples of children in Ile-Ife, Nigeria. African Journal of Biomedical Research, 15(2), 123-128.
5. Al-Seraih, A. A., Swadi, W. A., Al-hejjaj, M. Y., Al-Laijai, F. H., & Ghadban, A. K. (2022). Isolation and Partial Characterization of Glycolipopeptide Biosurfactant Derived from A Novel Lactiplantibacillus plantarum Lbp_WAM. Basrah Journal of Agricultural Sciences, 35(2), 78-98.

6. Belbase, A., Pant, N. D., Nepal, K., Neupane, B., Baidhya, R., Baidya, R., & Lekhak, B. (2017). Antibiotic resistance and biofilm production among the strains of *Staphylococcus aureus* isolated from pus/wound swab samples in a tertiary care hospital in Nepal. *Annals of clinical microbiology and antimicrobials*, 16(1), 15.
7. Bhatt, C. P., Karki, B. M. S., Baral, B., Gautam, S., Shah, A., & Chaudhary, A. (2014). Antibiotic susceptibility pattern of *Staphylococcus aureus* and methicillin-resistant *Staphylococcus aureus* in a tertiary care hospital. *Journal of Pathology of Nepal*, 4(7), 548-551.
8. Bholra, J., & Bhadekar, R. (2019). *In vitro* synergistic activity of lactic acid bacteria against multi-drug resistant staphylococci. *BMC complementary and alternative medicine*, 19(1), 1-8.
9. Bitrus, A., Peter, O., Abbas, M., & Goni, M. (2018). *Staphylococcus aureus*: a review of antimicrobial resistance mechanisms. *Veterinary Sciences: Research and Reviews*, 4(2), 43-54.
10. Bokharaei, N. M., Dallal, M. S., Pourmand, M. R., & Rajabi, Z. (2020). Antibiotic Resistance Pattern and Detection of *mecA* Gene in *Staphylococcus aureus* Isolated from Iranian Hamburger Samples. *Journal of food quality and hazards control*.
11. Brooks, G. F.; Carroll, K. C.; Butel, J. S. and Morse, S.A. ; Mietzner, T. A. (2014). *Jawetz and Adelbergs Medical Microbiology*. 27th.ed. The McGraw-Hill Medical, New York.
12. Carvalho, F. M., Mergulhão, F. J., & Gomes, L. C. (2021). Using Lactobacilli to Fight *Escherichia coli* and *Staphylococcus aureus* Biofilms on Urinary Tract Devices. *Antibiotics*, 10(12), 1525.
13. Cheatham, S., Thapaliya, D., Taha, M., Milliken, K., Dalman, M. R., Kadariya, J., ... & Smith, T. C. (2019). Prevalence of *Staphylococcus aureus* and methicillin-resistant *S. aureus* on environmental surfaces in Ohio nursing homes. *American journal of infection control*, 47(12), 1415-1419.
14. Chowdhury, D., Jhora, S. T., Khan, T. M., & Afroz, S. (2013). Evaluation of MRSA Chrome agar for the detection of methicillin resistant *Staphylococcus aureus*. *Ibrahim Medical College Journal*, 7(1), 1-4.
15. Cooper, B.S.; Medley, G.F.; Stone, S.P.; Kibbler, C.C.; Cookson, B.D.; Roberts, J.A.; Duckworth, G.; Lai, R.; and Ebrahim, S. (2014). Methicillin-resistant *Staphylococcus aureus* in hospitals and the community: Stealth dynamics and control catastrophes. *Proceedings of the National Academy of Sciences (PNAS) of the USA* .101(27):10,223-8.
16. den Heijer, C. D., van Bijnen, E. M., Paget, W. J., Pringle, M., Goossens, H., Bruggeman, C. A., and APRES Study Team. (2013). Prevalence and resistance of commensal *Staphylococcus aureus*, including methicillin-resistant *S. aureus*, in nine European countries: a cross-sectional study. *The Lancet infectious diseases*, 13(5), 409-415.
17. Diederer, B., van Duijn, I., van Belkum, A., Willemse, P., van Keulen, P., & Kluytmans, J. (2005). Performance of CHROMagar MRSA medium for detection of methicillin-resistant *Staphylococcus aureus*. *Journal of clinical microbiology*, 43(4), 1925–1927.
18. El-Nagdy, A. H., Abdel-Fattah, G. M., & Emarah, Z. (2020). Detection and control of biofilm formation by *Staphylococcus aureus* from febrile neutropenic patient. *Infection and Drug Resistance*, 13, 3091.
19. Fagade, O.E.; Ezeamagu, C.O.; Oyelade, A.A. & Ogunjobi, A.A. (2010). Comparative study of antibiotic resistance of *Staphylococcus* species isolated from clinical and environmental samples. *J. Techn. Rep.*, 13(3): 165-169.
20. Fatima, K., Indu, S., Meher, R., & Tariq, M. (2011). sharma SC. Detection of biofilm formation in *S. aureus*: Does it have a role in treatment. *Trends in medical research*, 6, 116-123.
21. Gurung, R. R., Maharjan, P., & Chhetri, G. G. (2020). Antibiotic resistance pattern of *Staphylococcus aureus* with reference to MRSA isolates from pediatric patients. *Future science OA*, 6(4), FSO464.
22. Hancock, V., Dahl, M., & Klemm, P. (2010). Abolition of biofilm formation in urinary tract *Escherichia coli* and *Klebsiella* isolates by metal interference through competition for fur. *Applied and environmental microbiology*, 76(12), 3836–3841.
23. Hentzer, M., Riedel, K., Rasmussen, T. B., Heydorn, A., Andersen, J. B., Parsek, M. R., ... & Givskov, M. (2002). Inhibition of quorum sensing in *Pseudomonas aeruginosa* biofilm bacteria by a halogenated furanone compound. *Microbiology*, 148(1), 87-102.
24. Jahan, M., Rahman, M., Parvej, M. S., Chowdhury, S. M. Z. H., Haque, M. E., Talukder, M. A. K., & Ahmed, S. (2015). Isolation and characterization of *Staphylococcus aureus* from raw cow milk in Bangladesh. *Journal of Advanced Veterinary and Animal Research*, 2(1), 49-55.
25. Karska-Wysocki, B., Bazo, M., & Smoragiewicz, W. (2010). Antibacterial activity of *Lactobacillus acidophilus* and *Lactobacillus casei* against methicillin-resistant *Staphylococcus aureus* (MRSA). *Microbiological research*, 165(8), 674–686.
26. Khanal, L. K., Adhikari, R. P., & Guragain, A. (2018). Prevalence of methicillin resistant *Staphylococcus aureus* and antibiotic susceptibility pattern in a tertiary hospital in Nepal. *Journal of Nepal Health Research Council*, 16(2), 172-174.
27. Kubba, M.A. (2006). Improvement of inhibition effect of probiotic against some bacterial isolate using prebiotic. M.Sc thesis. Al-Nahrain University
28. Looney, A. T., Redmond, E. J., Davey, N. M., Daly, P. J., Troy, C., Carey, B. F., & Cullen, I. M. (2017). Methicillin-resistant *Staphylococcus aureus* as a uropathogen in an Irish setting. *Medicine*, 96(14).
29. Luzzago, C., Locatelli, C., Franco, A., Scaccabarozzi, L., Gualdi, V., Viganò, R., and Cremonesi, P. (2014). Clonal diversity, virulence-associated genes and antimicrobial resistance profile of *Staphylococcus aureus* isolates from nasal cavities and soft tissue infections in wild ruminants in Italian Alps. *Veterinary microbiology*, 170(1-2), 157-161.
30. Mathur, T.; Singhal, S.; Khan, S.; Upadhyay, D. J. ; Fatima, T. and Rattan, A. (2006). Detection of biofilm formation among the clinical isolates of *Staphylococci*: An evaluation of three different screening methods. *Indian J. Med. Microb.* 24(1):25-29.
31. McFaddin, J. F. (2000). Coagulase test, p. 105-119. *Biochemical test for identification of medical bacteria*, 3rd ed. Williams & Wilkins, Philadelphia, Pa. Press.
32. Melo, P. D. C., Ferreira, L. M., Nader Filho, A., Zafalon, L. F., Vicente, H. I. G., & Souza, V. D. (2013). Comparison of methods for the detection of biofilm formation by *Staphylococcus aureus* isolated from bovine subclinical mastitis. *Brazilian Journal of Microbiology*, 44, 119-124.
33. Melo, T. A., Dos Santos, T. F., de Almeida, M. E., Junior, L. A. G. F., Andrade, E. F., Rezende, R. P., ... & Romano, C. C. (2016). Inhibition of *Staphylococcus aureus* biofilm by *Lactobacillus* isolated from fine cocoa. *BMC microbiology*, 16(1), 1-9.
34. Nataraj, B. H., Ramesh, C., & Mallappa, R. H. (2021). Characterization of biosurfactants derived from probiotic lactic acid bacteria against methicillin-resistant and sensitive *Staphylococcus aureus* isolates. *LWT*, 151, 112195.

35. Palavecino, E. (2007). Clinical, epidemiological, and laboratory aspects of methicillin-resistant *Staphylococcus aureus* (MRSA) infections. *Methicillin-Resistant Staphylococcus aureus (MRSA) Protocols*, 1-19.
36. Pillai, M. M., Latha, R., & Sarkar, G. (2012). Detection of methicillin resistance in *Staphylococcus aureus* by polymerase chain reaction and conventional methods: a comparative study. *Journal of laboratory physicians*, 4(2), 83–88.
37. Ramakrishna, P., Syed, A., Ashthami, V., Anju, M., & Safeera, M. (2014). Biofilm: Comparison between the *Staphylococcus aureus* and coagulase negative staphylococcus species isolated from a rural medical college hospital in North Kerala, India. *Int J Curr Microbiol App Sci*, 3(1), 23-29.
38. Saha, T. K., Begum, F., Kabir, S. L., Islam, M. S., and Khan, M. S. R. (2019). Characterization of bacterial isolates from skin lesions of sheep, goat and cattle in different rearing condition. *Asian Journal of Medical and Biological Research*, 5(2), 117-125.
39. Sato, T., Ito, R., Kawamura, M., & Fujimura, S. (2022). The Risk of Emerging Resistance to Trimethoprim/Sulfamethoxazole in *Staphylococcus aureus*. *Infection and Drug Resistance*, 15, 4779-4784.
40. Scudiero, O., Brancaccio, M., Mennitti, C., Laneri, S., Lombardo, B., Biasi, M. G. D., and Pero, R. (2020). Human Defensins: A Novel Approach in the Fight against Skin Colonizing *Staphylococcus aureus*. *Antibiotics*, 9(4), 198.
41. Shahi, K., Rijal, K. R., Adhikari, N., Shrestha, U. T., Banjara, M. R., Sharma, V. K., & Ghimire, P. (2018). Methicillin resistant *Staphylococcus aureus*: prevalence and antibiogram in various clinical specimens at Alka Hospital. *Tribhuvan University Journal of Microbiology*, 5, 77-82.
42. Singh, S. K. (2017). *Staphylococcus aureus* intracellular survival: A closer look in the process. *Virulence*, 8(8), 1506.
43. Tibebu, L., Belete, Y., Tigabu, E., & Tsegaye, W. (2021). Prevalence of *Staphylococcus aureus*, Methicillin-Resistant *Staphylococcus aureus* and Potential Risk Factors in Selected Dairy Farms at the Interface of Animal and Human in Bishoftu, Ethiopia. *Veterinary Medicine: Research and Reports*, 12, 241.
44. Versalovic, J. (2011). *Manual of clinical microbiology* (Vol. 1). American Society for Microbiology Press.
45. Xu, X., Peng, Q., Zhang, Y., Tian, D., Zhang, P., Huang, Y., ... & Shi, B. (2020). Antibacterial potential of a novel *Lactobacillus casei* strain isolated from Chinese northeast sauerkraut and the antibiofilm activity of its exopolysaccharides. *Food & function*, 11(5), 4697-4706.
46. Yousefi, M., Pourmand, M. R., Fallah, F., Hashemi, A., Mashhadi, R., & Nazari-Alam, A. (2016). Characterization of *Staphylococcus aureus* biofilm formation in urinary tract infection. *Iranian journal of public health*, 45(4), 485.